Alimera Sciences (ALIM) announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately. Most recently Maltz was the Chief Financial Officer with Orgenesis (ORGS), a publicly traded global biotech company transforming the processing of cell and gene therapies. Maltz will be taking on the role from Russell Skibsted. Skibsted’s departure is not the result of any disagreement with management concerning the Company’s operations or management. The Company also announced today that on January 2, 2024, in connection with Maltz’s joining as Chief Financial Officer, the Compensation Committee of the Board of Directors of the Company approved an inducement option to purchase up to 75,000 shares of common stock to Maltz.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALIM:
- Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences appoints Todd Wood, president, U.S. operations
- Alimera Appoints Maggie A. Pax to Its Board of Directors
